We specialise in the strategic development, management and analysis of programs that support Clinical Development; from compound selection to Phase I-IV clinical studies. ICON can support product design, development and registration, regulatory support and commercialisation of Biosimilars. recruitment of eligible participants is a challenge for any Are you ready?Serving governments, multinational public health organisations, and global NGOs.We have extensive experience in a broad range of therapeutic areas. represent a major unmet medical need. ICON provides full service outsourcing and flexible support for biotech specific needs such as due diligence and asset valuation. Data Management Fast delivery of high quality and meaningful data means that you can make well informed decisions earlier in the trial. Managing studies in all major geographies, we have established solid working relationships with the world’s leading investigators.ICON has conducted hundreds of clinical studies in both solid and haematological tumours, including experience with CAR-T therapies.ICON has recently led the development of 17 vaccines resulting in FDA/EMA approvals. into trial designs risks the need to spend more money ICON is a Global Contract Research Organisation (CRO). later on. Our services span the entire lifecycle of product development and commercialisation, and can be adapted to Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.Icon Clinical Research Ltd. provides clinical research services. ICON has conducted hundreds of clinical studies in both solid and haematological tumours, including experience with CAR-T therapies. Icon Clinical Research offers services worldwide. Other ICON Clinical Research Services include: Biostatistics Innovative clinical trial designs that take advantage of our in depth statistical expertise. In a recent podcast interview, ICON experts discuss the intricacies of CGT development, the solutions that will enable CGT development on a global basis, and the future of CGT clinical trials.Clinical development can better satisfy the evidence needs We are committed to exceeding the quality standards demanded by our clients, patients and regulatory authorities.Exploring the patient dynamic from different perspectivesKeeping your clinical trial on track in an evolving environment.Navigating the shift from traditional trial models to agile, patient-centric processes driven by digital health technologies.Find out more about estimands and how deploying this approach will improve the quality of clinical researchBest practices to accelerate operations while the world waits. ICON regularly contributes thought leadership to industry media publications and conferences, and has been recognised as one of the world’s leading Contract Research Organisations through a number of high-profile industry awards.Our mission is to help clients accelerate the development of COVID-19 is affecting how clinical trials are managed, in The Company focuses on planning management, execution, and analysis of clinical trials of clinical operations, medical and safety services, data management, biostatistics, and clinical development. We are currently working on a number of COVID-19 vaccine trials.We develop integrated technologies to significantly enhance the efficiency and productivity of clients’ drug and device development programs.With travel restrictions due to COVID-19, FIRECREST helps deliver and manage remote training for investigators.Connecting patients with the right trial in the right location.BioPharma companies and Medical Devices manufacturers face growing operational, regulatory and economic challenges. of payers, and not incorporating the needs of payers early in stark contrast to that in the EU, which has led the way Vaccines ICON has recently led the development of 17 vaccines resulting in FDA/EMA approvals.
We specialise in the strategic development, management and analysis of programs that support Clinical Development; from compound selection to Phase I-IV clinical studies. ICON can support product design, development and registration, regulatory support and commercialisation of Biosimilars. recruitment of eligible participants is a challenge for any Are you ready?Serving governments, multinational public health organisations, and global NGOs.We have extensive experience in a broad range of therapeutic areas. represent a major unmet medical need. ICON provides full service outsourcing and flexible support for biotech specific needs such as due diligence and asset valuation. Data Management Fast delivery of high quality and meaningful data means that you can make well informed decisions earlier in the trial. Managing studies in all major geographies, we have established solid working relationships with the world’s leading investigators.ICON has conducted hundreds of clinical studies in both solid and haematological tumours, including experience with CAR-T therapies.ICON has recently led the development of 17 vaccines resulting in FDA/EMA approvals. into trial designs risks the need to spend more money ICON is a Global Contract Research Organisation (CRO). later on. Our services span the entire lifecycle of product development and commercialisation, and can be adapted to Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.Icon Clinical Research Ltd. provides clinical research services. ICON has conducted hundreds of clinical studies in both solid and haematological tumours, including experience with CAR-T therapies. Icon Clinical Research offers services worldwide. Other ICON Clinical Research Services include: Biostatistics Innovative clinical trial designs that take advantage of our in depth statistical expertise. In a recent podcast interview, ICON experts discuss the intricacies of CGT development, the solutions that will enable CGT development on a global basis, and the future of CGT clinical trials.Clinical development can better satisfy the evidence needs We are committed to exceeding the quality standards demanded by our clients, patients and regulatory authorities.Exploring the patient dynamic from different perspectivesKeeping your clinical trial on track in an evolving environment.Navigating the shift from traditional trial models to agile, patient-centric processes driven by digital health technologies.Find out more about estimands and how deploying this approach will improve the quality of clinical researchBest practices to accelerate operations while the world waits. ICON regularly contributes thought leadership to industry media publications and conferences, and has been recognised as one of the world’s leading Contract Research Organisations through a number of high-profile industry awards.Our mission is to help clients accelerate the development of COVID-19 is affecting how clinical trials are managed, in The Company focuses on planning management, execution, and analysis of clinical trials of clinical operations, medical and safety services, data management, biostatistics, and clinical development. We are currently working on a number of COVID-19 vaccine trials.We develop integrated technologies to significantly enhance the efficiency and productivity of clients’ drug and device development programs.With travel restrictions due to COVID-19, FIRECREST helps deliver and manage remote training for investigators.Connecting patients with the right trial in the right location.BioPharma companies and Medical Devices manufacturers face growing operational, regulatory and economic challenges. of payers, and not incorporating the needs of payers early in stark contrast to that in the EU, which has led the way Vaccines ICON has recently led the development of 17 vaccines resulting in FDA/EMA approvals.